Corvus Pharmaceuticals, Inc. (CRVS): A/s Novo , 10% owner of Corvus Pharmaceuticals, Inc. purchased 70,000 shares on May 12, 2016. The Insider buying transaction was reported by the company on May 16, 2016 to the Securities and Exchange Commission. The shares were purchased at $10.00 per share for a total value of $700,000.00 , the company said in a SEC Form 4 Filing.
Company has been under the radar of several Street Analysts.Corvus Pharmaceuticals, Inc. is Initiated by Credit Suisse to Outperform. The Rating was issued on Apr 18, 2016.Corvus Pharmaceuticals, Inc. is Initiated by Guggenheim to Buy. The Rating was issued on Apr 18, 2016.